Canonical reference · statuses, dated
GLP-1 medications in 2026: every lane, one page, statuses dated
Approvals landed fast in 2025–2026 and stale labels breed contradictions — so this is the site’s single canonical medication reference. Every status carries a date; every compounded mention carries the standing line: compounded formulations use the same active ingredient as brand products but are not FDA-approved as finished drugs.
Injectables — the established core
Semaglutide — brand Wegovy (weight) / Ozempic (T2D); weekly; ~15% trial-average (STEP-1 context). Compounded: 503A patient-specific lane — status file; audited flat $119–$139/mo. Tirzepatide — Zepbound (weight + OSA indication) / Mounjaro (T2D); ~20% trial-average (OSA file); brand vials $299–$449 with the 45-day window; compounded audited flat $139–$169/mo. Liraglutide — daily legacy (Saxenda), largely superseded on efficacy.
Orals — the 2025–2026 arrivals
Wegovy tablet (oral semaglutide, weight): approved December 2025, pharmacies from January 2026; empty-stomach/30-minute protocol (rules file); from ~$149 lowest dose. Foundayo (orforglipron): approved April 1, 2026 — first GLP-1 pill with no food, water, or timing restrictions; ~12.4% highest-dose average; $149 launch-window low doses, ~$299+ higher — decision file. Rybelsus: oral semaglutide for T2D (distinct indication). Compounded sublingual/ODT: audited $165–$229 class with real caveats — evidence file.
Pipeline — filed or filing (not available)
CagriSema: NDA filed December 18, 2025; Q4-2026 guidance; not approved; no legal access outside trials — status file. Retatrutide: Phase-3 complete per company reporting; BLA guidance Q1-2027 — tracker. Pipeline names sold online today are unregulated — the filter file.
Coverage lanes
$50/mo Medicare Bridge (Jul 2026–Dec 2027, BMI tiers) for Wegovy / Zepbound KwikPen / Foundayo; ~$25 commercial cards; TrumpRx snapshots; Medicaid in ~13 states — decoded in the coverage file. Cash benchmark: the audited flat floor on the boards.